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Abstract
Background: Coronary artery disease (CAD) in adults ≤ 35 years of age is rare, but the incidence is 
on the rise and the risk factors for this age group are largely uncertain. Previous studies have shown 
that hyperuricemia (HUA) is an independent risk factor for CAD in the general population, whereas the 
role in adults ≤ 35 years of age with acute coronary syndrome (ACS) is unclear.
Methods: Patients, 18–35 years of age, diagnosed with ACS for the first time at the documented institu-
tion between January 2005 and December 2015, were enrolled in the current study. The severity of CAD 
was assessed by the Gensini score. Patients were divided into two groups according to the definition of 
HUA. The relationship between HUA and CAD severity was assessed based on multi-variate analysis.
Results: Seven hundred seventy-one participants fulfilling the criteria were included in this study 
(mean age, 31.6 years; 94.4% male). HUA, which was defined as a serum uric acid level ≥ 7.0 mg/dL 
(420μmol/L) in males and ≥ 6.0 mg/dL (357 μmol/L) in females, accounted for 37% of the participants. 
Multivariate analysis identified that HUA is an independent risk factor of CAD severity, as assessed by 
the Gensini score, in very young adults with ACS (OR 8.28; 95% CI 1.96–14.59; p = 0.01), and the 
effect of HUA on CAD severity was second only to diabetes mellitus.
Conclusions: Hyperuricemia was shown to be an independent risk factor for CAD severity in young 
adults with ACS (18–35 years of age). (Cardiol J 2019; 26, 3: 275–282)
Key words: coronary artery disease, hyperuricemia, Gensini score, severity,  
young adults
Introduction
Young populations, especially the population 
≤ 35 years of age, are often overlooked with re-
spect to the diagnoses of acute coronary syndrome 
(ACS), even in individuals with multiple risk fac-
tors; however, studies have demonstrated that 
the incidence of coronary artery disease (CAD) in 
young adults is following an ascending trend [1, 2]. 
Common risk factors for CAD, such as cigarette 
smoking, elevated body mass index (BMI), and 
diabetes mellitus (DM), are known to be associ-
ated with young patients; however, recent studies 
have shown that non-traditional risk factors, such 
as hyperuricemia (HUA), may also play a role in 
the development of CAD. Considering the increas-
ing incidence of HUA in a young population, this 
study was conducted to determine the relationship 
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between HUA and CAD severity in very young 
adults with ACS. 
Methods
Study population
In this single center, observational study, 
young adults, 18–35 years of age, diagnosed with 
ACS for the first time at Anzhen Hospital between 
1 January 2005 and 31 December 2015, were en-
rolled. The study exclusion criteria were as follows: 
missing uric acid data; gout, inflammatory diseases, 
autoimmune diseases, heart failure, and renal im-
pairment (an estimated glomerular filtration rate 
[eGFR] < 60 mL/min/1.73 m2); history of diuretic 
or anti-hypertension drug use (losartan potas-
sium and hydrochlorothiazide tablets, compound 
amiloride hydrochloride tablets, and irbesartan 
and hydrochlorothiazide tablets), which affect the 
level of uric acid, before admission; and previous 
percutaneous coronary intervention or coronary 
artery bypass grafting, congenital heart disease, 
cardiomyopathy and valvular heart disease. The 
study was approved by the Institutional Ethics 
Committee of Beijing Anzhen Hospital. Written in-
formed consent was obtained from each participant.
Laboratory data collection
Blood samples were obtained from all  study 
subjects by vein puncture after at least 12 h of 
fasting in the morning on the first day of admission 
and were analyzed using an automated biochemical 
analyzer to determine the levels of serum uric acid 
(SUA) and other laboratory indicators such as total 
cholesterol (TC), triglycerides (TG), high-density 
lipoprotein cholesterol (HDL-C) and low-density 
lipoprotein cholesterol (LDL-C).
Acute coronary syndromes refers to a group 
of clinical conditions generated by myocardial 
ischemia, including unstable angina, non-ST-
-segment elevation myocardial infarction and ST- 
-segment elevation myocardial infarction [3]. ACS 
was diagnosed based on elevated cardiac biomark-
ers with classic symptoms of acute myocardial 
ischemia and new onset ischemic electrocardio-
graphic abnormalities. Patients without elevated 
cardiac biomarkers were qualified to participate 
if symptoms of acute myocardial ischemia were 
accompanied by a new onset electrocardiographic 
changes [4]. Hypertension (HTN) was defined as 
a blood pressure ≥ 140/90 mmHg or using anti-HTN 
medications according to the 2010 Hypertension 
Prevention and Treatment Guideline [5]. DM 
was defined according to the 1999 World Health 
Organization diabetes diagnostic criteria [6]. A LDL-C 
level ≥ 130 mg/dL (3.4 mmol/L) was considered 
elevated, hypertriglyceridemia was defined as 
a TG ≥ 150 mg/dL (1.7 mmol/L), a HDL-C < 40 mg/ 
/dL (1.0 mmol/L) was considered low, and hyper-
cholesterolemia was defined as a TC ≥ 200 mg/dL 
(5.2 mmol/L). All of the above values were defined 
according to the 2016 Guidelines for the Preven-
tion and Treatment of Dyslipidemia in Chinese 
Adults [7]. The National Cholesterol Education 
Program Adult Treatment Panel III criteria [8] 
for the metabolic syndrome were used to diag-
nose study participants with metabolic syndrome. 
Based on published clinical guidelines, SUA levels 
≥ 7.0 mg/dL (420 μmol/L) in males and ≥ 6.0 mg/dL 
(357 μmol/L) in females were defined as HUA [9]. 
A personal history of HTN and DM, a family history 
of CAD, cigarette smoking, and alcohol consumption 
were collected from electronic medical records. 
Gensini score and angiographic analysis
Coronary angiography (CAG) was performed 
using a standard technique. Coronary angiograms 
were analyzed by two experienced interventional 
cardiologists blinded to patient clinical information. 
CAD was defined as a luminal diameter stenosis 
≥ 50% in any of the major epicardial coronary arte-
ries, including the left main, left anterior descend-
ing, left circumflex, and right coronary arteries and 
the main branches of these arteries. Patients with 
acute myocardial infarction were also considered to 
have CAD. The severity of CAD was evaluated by 
the Gensini score. Based on the baseline diagnostic 
angiogram, the Gensini score was computed by as-
signing a severity score to each coronary stenosis 
according to the degree of luminal narrowing. This 
number was then multiplied by a factor that took 
into account the geographic importance of the le-
sion location in the coronary arteries. The Gensini 
score was then expressed as the sum of scores of 
all coronary arteries [10]. 
Statistical analyses
Continuous variables are presented as the 
mean ± standard deviation (normal distribution) or 
as the median with interquartile range (non-normal 
distribution). Categorical variables are presented 
as frequencies or percentages. Comparisons of 
normal distribution variables between two groups 
were achieved using unpaired t-tests. Comparisons 
of non-normal distribution variables between two 
groups were performed using the Mann-Whitney 
U test. For comparisons of categorical variables, 
c2 tests were used. The significant variables in the 
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univariate analysis were brought into a multivari-
ate linear regression model to identify predictors 
of CAD. The relationship between HUA and the 
severity of CAD was assessed with multi-variate 
linear regression analysis. A p value ≤ 0.05 (two-
-sided) was considered statistically significant. All 
analyses were performed with the statistical soft-
ware package R and EmpowerStats (http://www.
empowerstats.com, X&Y Solutions, Inc., Boston, 
MA, USA) [11]. 
Results
Patient demographics
A total of 771 participants fulfilling the criteria 
were included in this observational study (mean 
age, 31.6 years; 94.4% males). Figure 1 shows 
the study flow chart. Two hundred eighty-five 
participants were included in the HUA group, and 
the remaining 486 participants were included in 
the normouricemia group. The baseline charac-
teristics are shown in Table 1. Male gender, HTN, 
and metabolic syndrome were more prevalent in 
the HUA group than the normouricemic group 
(p < 0.05). The HUA group also had a decreased 
HDL-C level (p < 0.001). Moreover, the serum 
creatinine and TG levels, and BMI were increased 
in the HUA group (p < 0.001). The other factors 
which were analyzed (LDL-C, DM, family history 
of CAD, and alcohol consumption) were not associ-
ated with HUA.
Analysis of CAG 
Analysis of the coronary angiographic findings 
demonstrated that multi-vessel disease was more 
prevalent in the HUA group (47.5% vs. 38.1%; 
p = 0.01). Moreover, the single-vessel disease rate 
was decreased and the triple-vessel disease rate 
was increased in the HUA group (p = 0.036). Five 
hundred four (54.1%) patients underwent coronary 
stent implantation in the current study. In addition, 
patients undergoing stenting whose number of 
stents were between 4 and 7 were more common 
in the HUA group (p = 0.026; Table 2).
Univariate analysis of traditional  
CAD risk factors
Univariate analysis showed that the traditional 
CAD risk factors, such as DM, LDL-C and BUN 
levels, were significantly associated with the 
severity of CAD (p < 0.05). Univariate analysis 
also showed that HUA plays a prominent role in 
Figure 1. Flow chart of the study shows participant selection based on the inclusion and exclusion criteria among 
young adults 18–35 years of age with the diagnosis of acute coronary syndrome for the first time at this institution. 
A total of 771 participants were included in the analysis; CAD — coronary artery disease.
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the severity of CAD (odds ratio [OR] 6.85; 95% 
confidence interval [CI] 1.00–12.72; p = 0.022). 
In contrast, risk factors, such as current smokers, 
a family history of CAD, TG, HTN and metabolic 
syndrome were not significantly related to the 
severity of CAD (Table 3). 
Multi-variate linear regression analysis 
model of different CAD risk factors
A multi-variate linear regression analysis 
model further showed that traditional CAD risk 
factors (DM [OR 19.21; 95% CI 10.68–27.75; p < 
< 0.001] and LDL-C [OR 0.14; 95% CI 0.07–0.20; 
p < 0.001]) and a non-traditional CAD risk factor 
(HUA [OR 8.28; 95% CI 1.96–14.59; p = 0.01]) 
were significant risk factors for the severity of 
CAD after adjusting for confounding factors (Fig. 2).
Discussion
This is the largest study to date investigating 
the relationship between HUA and severity of CAD 
in adults ≤ 35 years of age. The most relevant find-
ing of the current study was that HUA is an inde-
pendent risk factor for CAD severity. Furthermore, 
the effect of HUA was shown to be only second to 
DM on CAD severity in this specific population of 
young adults.
Previous studies [12, 13] have investigated 
the relationship between HUA and the severity of 
CAD; however, the current study is the only study 
investigating HUA in a young ACS population. Du-
ran et al. [14] studied 246 middle-aged and elderly 
non-diabetic and non-hypertensive patients with 
ACS and reported a positive association between 
HUA and angiographic severity of ischemic heart 
disease (Gensini score). The results of the Duran 
et al. study [14] are in agreement with our data; 
however, the Duran et al. [14] study had a smaller 
sample size and the participants were older. In 
young adults, the relationship between HUA and 
the progression of CAD has also been reported. 
A study published in 2011 [15] involving a non-
CAD population 40 ± 4 years of age (CARDIA 
database) suggested that SUA levels are directly 
related to the occurrence and severity of coronary 
calcifications (subclinical coronary atherosclerosis 
indicators) independent of traditional risk factors. 
The study showed that a strong correlation exists 
between high uric acid levels and atherosclerosis, 
which in turn suggested that HUA may also be as-
sociated with the formation and severity of CAD in 
Table 1. Baseline clinical characteristics in normouricemic and hyperuricemic patients.
Normouricemic patient  
group (n = 486)
Hyperuricemic patient  
group (n = 285)
P
Baseline characteristics
Age [years] 31.6 ± 3.4 31.7 ± 3.5 0.973
Male 452 (93.0%) 276 (96.8%) 0.025
Alcohol consumption 115 (23.7%) 79 (27.7%) 0.210
BUN [mg/dL] 12.12 ± 4.85 12.75 ± 4.71 0.080
Serum creatinine [mg/dL] 0.86 ± 0.17 0.93 ± 0.19 < 0.001
Triglycerides [mg/dL] 156.82 (110.75–220.61%) 200.24 (140.87–300.35%) < 0.001
HDL-C [mg/dL] 35.71 ± 8.15 33.87 ± 7.72 0.002
LDL-C [mg/dL] 113.96 ± 46.35 115.87 ± 47.75 0.587
Total cholesterol [mg/dL] 176.60 ± 53.79 183.68 ± 58.10 0.089
Fasting glucose [mg/dL] 104.88 ± 34.24 103.29 ± 30.84 0.519
BMI [kg/m2] 27.31 ± 3.97 28.86 ± 4.20 < 0.001
Traditional coronary risk factors
Current smokers 323 (66.5%) 203 (71.2%) 0.170
Family history of CAD 70 (14.4%) 43 (15.1%) 0.795
Hypertension 186 (38.3%) 136 (47.7%) 0.010
Diabetes mellitus 81 (16.7%) 43 (15.1%) 0.565
Metabolic syndrome 257 (53.1%) 193 (68.9%) < 0.001
Values are given as the mean ± standard deviation, median with interquartile range, or number (%). BUN — blood urea nitrogen; HDL-C — 
high-density lipoprotein cholesterol; LDL-C — low-density lipoprotein cholesterol; BMI — body mass index; CAD — coronary artery disease
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young adults; however, this conclusion was derived 
from non-CAD participants. An observational study 
[16], which included 607 premenopausal women, 
showed that patients with higher levels of SUA had 
an increased rate of multi-vessel disease. Another 
study involving SUA levels and premature CAD 
(< 45 years of age) in 2015 [17] showed that SUA 
levels > 8 mg/dL are predictive of an increased 
risk of three-vessel disease (OR 2.345; 95% CI 
1.335–4.119) independent of traditional cardiovas-
cular risk factors. The definition of HUA in this 
study [17] was the same as the current study and 
the findings are consistent with the present study 
regarding the relationship between HUA and the 
number of diseased vessels, the participants, 
however, were older than the participants in the 
current study. Moreover, we concluded that the 
correlation between HUA and the Gensini score 
was more clinically meaningful than the number 
of diseased vessels in describing the angiographic 
severity of CAD. Thus, the current study has 
great value compared with previous studies [17] 
confirming the significance of HUA with CAD in 
a very young population.
The current study showed that HUA may 
be related to patients with HTN, metabolic syn-
drome and an increased TG level, however, after 
multivariate regression analysis to eliminate the 
impact of other CAD risk factors, HUA still plays 
an independent role in the development of CAD. 
Current studies have drawn many different conclu-
sions on the pathologic mechanism of uric acid in 
the development of CAD [12, 13, 18–21]. Uric acid 
can crystallize into the formation of monosodium 
urate crystals, which can result in tissue damage 
through an inflammatory response process, and 
thus participate in the occurrence of CAD [22]. In 
addition to the effect of monosodium urate crystals, 
there is agreement on the notion that even asymp-
tomatic HUA can induce tissue injury, particularly 
at the level of coronary vessels [23, 24]. Studies 
have shown that HUA can lead to CAD through 
a number of mechanisms, such as stimulating vaso-
constriction involving an inflammatory process, 
Table 2. Clinical features, angiographic findings, and medical treatment based on the definition of  
hyperuricemia in coronary artery disease patients.
Baseline characteristics Normouricemic patients  
(n = 486)
Hyperuricemic patients  
(n = 285)
P
Clinical characteristics
Unstable angina 184 (37.9%) 132 (46.3%) 0.021
NSTEMI 75 (15.4%) 34 (11.9%) 0.178
STEMI 227 (46.7%) 119 (41.7%) 0.182
Angiographic findings of vessel involvement 0.036
None 41 (8.7%) 16 (5.6%)
Single vessel 252 (53.3%) 133 (46.8%)
Double vessel 93(19.7%) 62 (21.8%)
Triple vessel 87 (18.4%) 73 (25.7%)
Left main disease 29 (6.0%) 23(8.1%) 0.261
Multi-vessel 180 (38.1%) 135 (47.5%) 0.01
Treatment 0.421
Drug 111 (22.8%) 56 (19.6%)  
Intervention 324 (66.7%) 203 (71.2%)  
Coronary artery bypass grafting 51 (10.5%) 26 (9.1%)  
Number of stents per patient: 0.026
0 111 (26.4%) 56 (22.5%)
1 184 (43.7%) 109 (43.8%)
2 80 (19.0%) 44 (17.7%)
3 33 (7.8%) 18 (7.2%)
4~7 13 (3.1%) 22 (8.8%)
Values are given as the number (%). NSTEMI — non-ST-segment elevation myocardial infarction; STEMI — ST-segment elevation myocardial 
infarction
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Table 3. Univariate analysis of coronary artery disease risk factors.
Variables Statistics Crude HR (95% CI) P 
Age 31.64 ± 3.43 0.67 (–0.17, 1.50) 0.117
Gender:
Female 
Male
43 (5.56) 
730 (94.44)
2.41 (–10.02, 14.84)  
1.0
0.7039
Hyperuricemia 285 (36.96) 
486 (63.04)
6.85 (1.00, 12.72) 
1.0
0.022
BUN 12.35 ± 4.81 0.78 (0.19, 1.37) 0.0098
Serum creatinine 0.89 ± 0.18 –7.92 (–23.65, 7.81) 0.324
BMI 27.9 ± 4.12 0.07 (–0.65, 0.80) 0.841
Alcohol consumption:
Yes 
No
194 (25.1) 
579 (74.9)
–5.54 (–12.11, 1.02)  
1.0 
0.0983
Current smokers:
Yes
No
527 (68.18) 
246 (31.82)
4.37 (–1.74, 10.48) 
1.0 
0.162
Family history of CAD:
Yes 
No
113 (14.62) 
660 (85.38)
5.17 (–2.82, 13.15) 
1.0 
0.205
Hypertension:
Yes 324 (41.91) –4.11 (–9.85, 1.63) 0.161
No 449 (58.09) 1.0 
Diabetes mellitus:
Yes 124 (16.04) 15.48 (7.77, 23.19) < 0.001
No 649 (83.96) 1.0 
Metabolic syndrome:
Yes 
No
450 (58.9) 
314 (41.1)
3.25 (–2.57, 9.07) 
1.0 
0.274
Total cholesterol 179.2 ± 55.48 0.12 (0.07, 0.17) < 0.0001
Triglycerides 214.54 ±174.49 0.02 (0.00, 0.03) 0.0532
LDL-C 114.66 ± 46.84 0.13 (0.07, 0.19) < 0.0001
HDL-C 35.04 ± 8.04 –0.37 (–0.73, –0.01) 0.0427
Values are given as mean ± standard deviation or number (%). BUN — blood urea nitrogen; CI — confidence interval; HDL-C — high-density 
lipoprotein cholesterol; HR — hazard ratio; LDL-C — low-density lipoprotein cholesterol; BMI — body mass index; CAD — coronary artery 
disease
Figure 2. Forest plot of multi-variate linear regression analysis model of different coronary artery disease (CAD) risk 
factors. HDL-C — high-density lipoprotein cholesterol; LDL-C — low-density lipoprotein cholesterol; BMI — body 
mass index; CI — confidence interval.
www.cardiologyjournal.org 281
Sai Lv et al., Hyperuricemia and CAD in adults 35 years of age and younger with ACS 
causing oxidative stress and impairing endothelial 
function [25–28]. These mechanisms are probably 
related to the incidence and progression of CAD 
in young adults.
Patient groups < 35 years of age are identi-
fied as very young in the literature [29, 30]. In the 
current study, the age range of participants was 
narrowed to 18–35 years in an effort to determine 
the correlation between HUA and the severity of 
CAD (a predictor of adverse outcomes in CAD) 
in a specific group (very young adults). Although 
traditional factors are vital for the prognosis of 
CAD, HUA was also shown to be an independent 
risk factor for CAD severity in the current study. 
Thus, the clinical significance of the current study 
involves increasing awareness of the importance 
of the uric acid level in patients ≤ 35 years of age. 
Clinicians should further instruct patients with 
asymptomatic HUA to pay more attention to eating 
habits, including a low purine diet and consuming 
less alcohol to control uric acid levels to within the 
normal range. More importantly, HUA was shown 
to be associated with the prognosis of CAD in 
young patients in the current study, as evidenced 
by an increased number of implanted stents as-
sociated with poor prognosis of CAD in the HUA 
group. Thus, the intention was to carry out an in-
depth study in the future to determine whether or 
not HUA is correlated with the prognosis of young 
patients after percutaneous coronary intervention 
and whether or not reducing HUA can decrease the 
severity of CAD.
Limitations of the study
There were several limitations to this study. 
First, this was not a randomized trial, but an obser-
vational study. Second, to define a risk factor with 
certainty, one has to demonstrate that reducing the 
factor can improve prognosis. Large randomized 
trials should be carried out to determine whether 
or not urate-lowering therapy has beneficial effects 
for reducing CAD mortality, thus potentially provid-
ing new therapeutic methods for the prevention 
and treatment of CAD. Third, in this study the 
Gensini score was used rather than the Syntax 
score to assess CAD severity. Because some 
patients were treated 10 years ago, and severity 
was assessed by CAG reports instead of reading 
the coronary angiogram, the Syntax score was not 
calculated, however, previous studies have verified 
the relevance and equivalence, with none inferior 
to the other [31].
Conclusions
In young adults with ACS (≤ 35 years of age), 
HUA is an independent risk factor for the severity 
of CAD after adjusting for potential confounding 
variables. 
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